Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15107325 | 0.85 | — | — | |
| SCHEMBL1129467 | 0.84 | NOD1 (0.36) | — | |
| SCHEMBL20160296 | 0.82 | KDM4E (0.35) | L3MBTL1HDAC2USP2HDAC1HDAC6 | |
| SCHEMBL21184224 | 0.78 | CA1 (0.32) | — | |
| SCHEMBL15107352 | 0.78 | TAS1R3 (0.46) | CYP2C9L3MBTL1HDAC2KMT2APOLB | |
| SCHEMBL24335308 | 0.76 | CTSK (0.44) | CYP2C9HDAC1HDAC6 | |
| SCHEMBL16853383 | 0.73 | HDAC2 (0.38) | CYP2C9L3MBTL1HDAC2KMT2APOLB | |
| SCHEMBL26257173 | 0.73 | HDAC2 (0.38) | CYP2C9L3MBTL1HDAC2KMT2APOLB | |
| SCHEMBL15101812 | 0.71 | CA1 (0.33) | — | |
| SCHEMBL15101810 | 0.71 | CA14 (0.36) | CYP2C9KMT2ATSHRBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487128-B2 | Protection of normal cells | CHS PHARMA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20090326073-A1 | PROTECTION OF NORMAL CELLS | FLORIDA ATLANTIC UNIVERSITY | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326073-A1 | PROTECTION OF NORMAL CELLS | ERCC1, ERCC2, XPA | CYP2C9 1095/4885L3MBTL1 1715/4885HDAC2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.